Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.
作者信息
Schmitt Manfred, Mengele Karin, Gkazepis Apostolos, Napieralski Rudolf, Magdolen Viktor, Reuning Ute, Harbeck Nadia
机构信息
Clinical Research Unit, Department of Obstetrics and Gynecology Klinikum rechts der Isar, Technical University of Munich, Germany.
出版信息
Breast Care (Basel). 2008;3(s2):3-10. doi: 10.1159/000151737. Epub 2008 Oct 15.
Abstract
摘要
相似文献
1
Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.
Breast Care (Basel). 2008;3(s2):3-10. doi: 10.1159/000151737. Epub 2008 Oct 15.
2
3
Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients.
Breast Cancer Res Treat. 1998 May;49(1):41-50. doi: 10.1023/a:1005997421733.
4
5
Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Cancer. 1996 Mar 15;77(6):1079-88. doi: 10.1002/(sici)1097-0142(19960315)77:6<1079::aid-cncr12>3.0.co;2-z.
6
7
8
Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
Ann Surg Oncol. 2003 Oct;10(8):948-53. doi: 10.1245/aso.2003.03.518.
9
Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
J Clin Oncol. 2002 Feb 15;20(4):1000-7. doi: 10.1200/JCO.2002.20.4.1000.
10
Antigen levels of urokinase type plasminogen activator and its inhibitors in primary breast cancer.
Z Naturforsch C J Biosci. 2002 Mar-Apr;57(3-4):366-71. doi: 10.1515/znc-2002-3-428.
引用本文的文献
1
uPA-PAI-1 heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils.
EMBO Mol Med. 2021 Jun 7;13(6):e13110. doi: 10.15252/emmm.202013110. Epub 2021 May 16.
2
Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications.
Int J Mol Sci. 2021 Apr 22;22(9):4358. doi: 10.3390/ijms22094358.
3
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Front Oncol. 2018 Feb 12;8:24. doi: 10.3389/fonc.2018.00024. eCollection 2018.
4
Domain retention in transcription factor fusion genes and its biological and clinical implications: a pan-cancer study.
Oncotarget. 2017 Nov 24;8(66):110103-110117. doi: 10.18632/oncotarget.22653. eCollection 2017 Dec 15.
5
Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.
Pathologe. 2017 Nov;38(Suppl 2):180-191. doi: 10.1007/s00292-017-0375-9.
6
Overexpression of MMP-3 and uPA with Diminished PAI-1 Related to Metastasis in Ductal Breast Cancer Patients Attending a Public Hospital in Mexico City.
J Immunol Res. 2016;2016:8519648. doi: 10.1155/2016/8519648. Epub 2016 Nov 15.
7
Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Tumour Biol. 2015 Sep;36(10):8193-200. doi: 10.1007/s13277-015-3573-1. Epub 2015 May 21.
8
Common protein biomarkers assessed by reverse phase protein arrays show considerable intratumoral heterogeneity in breast cancer tissues.
PLoS One. 2012;7(7):e40285. doi: 10.1371/journal.pone.0040285. Epub 2012 Jul 5.
9
uPA and PAI-1-Related Signaling Pathways Differ between Primary Breast Cancers and Lymph Node Metastases.
Transl Oncol. 2012 Apr;5(2):98-104. doi: 10.1593/tlo.11268. Epub 2012 Apr 1.
本文引用的文献
1
A PROTEOLYTIC ENZYME OF SERUM: CHARACTERIZATION, ACTIVATION, AND REACTION WITH INHIBITORS.
J Gen Physiol. 1945 Jul 20;28(6):559-83. doi: 10.1085/jgp.28.6.559.
2
Fibrinolysis; its mechanism and significance.
Blood. 1948 Oct;3(10):1167-87.
3
Epigenetics in cancer.
N Engl J Med. 2008 Mar 13;358(11):1148-59. doi: 10.1056/NEJMra072067.
4
Systematic review: gene expression profiling assays in early-stage breast cancer.
Ann Intern Med. 2008 Mar 4;148(5):358-69. doi: 10.7326/0003-4819-148-5-200803040-00208. Epub 2008 Feb 4.
5
6
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
J Clin Oncol. 2007 Nov 20;25(33):5287-312. doi: 10.1200/JCO.2007.14.2364. Epub 2007 Oct 22.
7
Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression.
Am J Clin Pathol. 2007 Sep;128(3):404-13. doi: 10.1309/K4JAF2NMD5EJU67Y.
8
Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?
Nat Rev Cancer. 2007 Jul;7(7):545-53. doi: 10.1038/nrc2173.
9
Inhibition of PAI-1 expression in breast cancer carcinoma cells by siRNA at nanomolar range.
Biochimie. 2007 Oct;89(10):1228-33. doi: 10.1016/j.biochi.2007.03.017. Epub 2007 Apr 2.
10
Shaping the future of biomarker research in breast cancer to ensure clinical relevance.
Nat Rev Cancer. 2007 Apr;7(4):309-15. doi: 10.1038/nrc2113.
Zotero 插件